Clinical Trial

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-15
Trial Details
NCT Number NCT07514260
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 24 participants
Start Date 2026-03-31
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14